Indoco Remedies Achieves Zero FDA Observations at Mumbai API Manufacturing Facility
核心洞察
Indoco Remedies' active pharmaceutical ingredients manufacturing facility at Patalganga completed US FDA (搜索) inspection with zero Form 483 observations, demonstrating exceptional regulatory compliance.
The successful inspection reflects the company's commitment to quality standards and operational excellence in pharmaceutical manufacturing processes.
Indoco operates as a fully integrated research-oriented pharmaceutical company with $180 million turnover and over 6,000 employees globally.
Indoco Remedies Limited has successfully completed a US Food and Drug Administration inspection of its active pharmaceutical ingredients manufacturing facility at Patalganga, Navi Mumbai, with zero Form 483 observations. This achievement represents a significant regulatory milestone for the fully integrated pharmaceutical company, demonstrating adherence to the highest standards of quality and compliance.
Regulatory Excellence Achievement
The FDA inspection concluded without any Form 483 observations, which are issued when inspectors identify conditions that may constitute violations of FDA regulations. This clean inspection result reflects Indoco's robust quality management systems and manufacturing processes at the API facility.
"This successful USFDA inspection is a testament to the strong quality culture and compliance in every process and every product. We remain committed to strengthening our systems to deliver safe and efficacious medicines across the globe," said Aditi Panandikar, Managing Director of Indoco Remedies Limited.
Company Profile and Manufacturing Capabilities
Indoco Remedies operates as a research-oriented pharmaceutical company with a global presence, generating annual revenues of $180 million. The organization employs over 6,000 people worldwide, including more than 400 skilled scientists and field staff who form the backbone of its operations.
The company maintains an extensive manufacturing network comprising 11 facilities - seven dedicated to finished dosage forms and four for active pharmaceutical ingredients. These facilities are supported by a state-of-the-art research and development center and a contract research organization facility. The manufacturing sites have received approvals from major regulatory authorities, including the USFDA and UK-MHRA (搜索).
Market Presence and Product Portfolio
Indoco's domestic operations generate more than 106 million prescriptions annually from over 240,000 doctors across various medical specialties. The company operates 10 domestic marketing divisions with a diverse brand portfolio spanning multiple therapeutic segments including gastro-intestinal, respiratory, anti-infectives, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, pain management, and gynecology.
Key brands in Indoco's portfolio include Cyclopam (搜索), Febrex Plus (搜索), Sensodent-K (搜索), Karvol Plus (搜索), ATM (搜索), Oxipod (搜索), Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, and Otorex.
Global Operations
On the international front, Indoco has established strategic partnerships with large generic pharmaceutical companies across the globe, enabling the company to develop and manufacture pharmaceutical products for both Indian and international markets. This global network supports the company's mission to deliver safe and efficacious medicines worldwide.